A phase 1 study of ON 123300 for the treatment of cancer
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2018
At a glance
- Drugs ON 123300 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors HanX Biopharmaceuticals
- 13 Nov 2018 According to an Onconova Therapeutics media release, Investigational New Drug (IND) filing is expected to be submitted in the first half of 2019.
- 24 Apr 2018 New trial record
- 19 Apr 2018 According to an Onconova Therapeutics media release, HanX Biopharmaceutical plans to initiate a clinical studies in China.